AbbVie is committed to working closely with health care professionals to improve patient health across the globe. The information exchanged through these relationships has led to newer and better therapies and, most importantly, enhanced care for patients.
We work with health care professionals primarily in the research and development process and in medical education. Their expertise helps us develop and enhance products and therapies to treat conditions including HIV, arthritis, immunological and metabolic disorders, heart disease, and cancer.
Collaboration in Research and Development
Developing new products and therapies can take many years and significant financial commitment to ensure products are safe and effective for patients. Health care professionals are a crucial source of information regarding use of medicine in the real world, as well as in clinical trials. Without the benefit of that information, we would be unable to improve existing products and deliver innovation in patient care that has been the hallmark of medical advancement. Our interactions with health care professionals during the development process are essential to providing patients with products that are backed by extensive clinical experience.
Collaboration in Education
Continuing education is key to ensuring the best treatment is accompanied by the right knowledge to fully meet the needs of patients. We offer programs and opportunities for health care professionals in support of medical and patient education. We believe these programs increase health care knowledge and improve patient care. For example:
- We exchange information with health care professionals through in-office interactions in which we share some of the latest data around treatment therapies and research.
- We provide opportunities for health care professionals to engage in peer-to-peer discussions, sharing the latest in treatment regimens and patient care.
- We provide educational materials, such as journal articles, and facilitate health care professional education on diseases and products.
Acting with Transparency
We believe interactions with health care professionals bring value to patient care. Our interactions with them are guided by openness and transparency. This is especially important when it comes to financial payments or other forms of value provided. Demonstrating the integrity of our relationships with health care professionals through transparency and disclosure is an important part of these relationships.
The Sunshine Act became federal law in 2010. The Act requires health care manufacturers, including AbbVie, to track financial transactions with certain health care providers and health care organizations and to disclose those transactions on an annual basis. As part of AbbVie's Corporate Integrity Agreement, AbbVie's U.S. business has agreed to post payments to physicians that would be reported annually under the Sunshine Act on a quarterly basis. We support the Sunshine Act and its goal of providing the public greater visibility into interactions between the health care industry and health care professionals to ensure public trust and confidence.
The report is based on transactional data that has been aggregated at a particular point in time; some payments and transfers of value that take place during the reporting period may be included in the next quarter's report. Posted data may not correlate to state transparency reports due to differences in the scope and requirements between the various transparency laws. Changes or additions that are identified after the report is posted will be accounted for in the next quarter's report. Due to the requirements for reporting related entities/payees, some payments shown on the report are included more than once.
The types of payments and transfers of value included in the report are as follows:
Business Meals, which include reimbursed amounts for meals incurred in the course of providing contracted-for services such as consulting and research; and meals provided in connection with an educational or business discussion
Business Travel, which includes reimbursed amounts and the value of directly-provided transportation (e.g., airfare, taxi service) incurred in the course of providing contracted-for services, such as consulting and research
Educational Materials and Items, which includes reference material such as journal articles, textbooks, and anatomical models
Professional Services, which include payments for contracted-for services, such as speaking at an educational seminar or serving on a data safety monitoring board
Research Related Payments, which include payments for research and clinical trial activities, royalties, and license fees
For individuals with a year-to-date total of $100 or less, individual payments and transfers of value less than $10 are excluded from the report, as provided for by the Sunshine Act.
GRANTS & DONATIONS – U.S.
AbbVie is committed to supporting programs aimed at increasing the understanding of scientific, clinical and health care issues that improve patient care. We partner with a broad range of organizations to help address today’s health care challenges. We want to do our part to ensure that patients, and the health care providers who treat them, receive the information and support they need.
This report discloses charitable donations, educational grants, fellowships and scholarships, patient support and corporate sponsorships. Recipients include medical and other health care professional organizations, patient organizations, academic institutions, hospitals, medical education companies and other scientific associations. All AbbVie grant requests originating from the U.S. and Puerto Rico are processed by a centralized grant management department.
In addition, support from the non-profit, philanthropic AbbVie Foundation will be reported in an annual Internal Revenue Service 990-PF filing by May 15, 2013. This information will be available on the web site www.foundationcenter.org.
The posted reports include individual direct payments of more than $200 from Abbvie’s U.S. and Puerto Rico businesses. The reports may be updated from time to time.
If you have questions on the data contained in the reports, please email TransparencyReporting@abbvie.com.